#3300

COPY OF PAPERS ORIGINALLY FILED

PATENT

N THE LIMITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/029,206

Filed: December 21, 2001

For: OLIGOPEPTIDE TREATMENT OF

ANTHRAX

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-5222US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 2031:

2-4-02 Date of Deposit

Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1/ii)

Typed/printed name of person whose signature is

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08A be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Attorney Docket No.: 2183-5222US

DOCUMENTS

U.S. Patent Documents

U.S. Patent No.

Inventor

Issue Date

6,319,504

Gallo et al.

11-20-2001

Other Documents

CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-81, 166, The American Association of Immunologists, USA.

FRIEDLANDER, Tackling anthrax, Nature, November 8, 2001, pp. 160-61, Vol. 414.

MEDZHITOV, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-45, Vol. 1.

Applicants offer to supply any explanation or discussion of the documents that the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041

Attorney for Applicants

TRASKBRITT, PC P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: February 4, 2002

ACT/by

Enclosures: Form PTO-1449 or PTO/SB/08A

Copy of documents cited

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are described to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Solid Hallist			
CANII.	Complete if Known			
Application Number	10/029,206			
Filing Date	12/21/2001			
First Named Inventor	Khan et al.			
Group Art Unit	To be assigned			
Examiner Name	To be assigned			
Attorney Docket Number	2183-5222US			

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Document Number Kind Code² (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear	
		6,319,504	Gallo et al.	11-20-2001		
				0	COPY OF PAPERS	
					GINA PAR	
		 			TO THE PARTY OF TH	
					160	
		·				
				18		
				78		

	FOREIGN PATENT DOCUMENTS							
Examiner Cite No.1	Cito .	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	Ī
	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆	
		<u> </u>						
		 	 					
		 						
		 						
		-						
		 						
	-	 						
		,	<u> </u>					

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

COPY OF PAPERS **ORIGINALLY FILED**

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/029,206 INFORMATION DISCLOSURE Filing Date 12/21/2001 STATEMENT BY APPLICANT First Named Inventor Khan et al. Group Art Unit To be assigned (use as many sheets as necessary) **Examiner Name** To be assigned Sheet of 2 Attorney Docket Number 2183-5222US

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-81, 166, The American Association of Immunologists, USA.					
		FRIEDLANDER, Tackling anthrax, Nature, November 8, 2001, pp. 160-61, Vol. 414.					
		MEDZHITOV, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-45, Vol. 1.					
J							
	,						
			<u>_</u>				

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.